Log in to search using one of your social media accounts:

 

Discovery the phenomenon of polymorphism in the atomic structure of the methylprednisolone aceponate
(Lobachevsky University) UNN researchers have discovered the phenomenon of polymorphism in the atomic structure of the methylprednisolone aceponate crystal. They managed to synthesize a single crystal of corticosteroid hormone methylprednisolone aceponate, which was of a sufficient size for X-ray diffraction studies. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 15, 2018 Category: International Medicine & Public Health Source Type: news

GSK seeks expanded label for Trelegy Ellipta inhaler in EU
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) have submitted data to the European Medicines Agency in the hopes of expanding the label for its once-daily, triple combination inhaler, Trelegy Ellipta. The drug-device combo was approved in Europe in November last year as a maintenance treatment for adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a inhaled corticosteroid combined with a long-acting beta-adrenergic agonist. GSK and Innoviva hope that data from its Impact trial will support the product’s use in a broader populati...
Source: Mass Device - February 14, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Widely Used COPD Meds Tied to Increased Fracture Risk
TUESDAY, Feb. 13, 2018 -- Many patients with chronic obstructive pulmonary disease (COPD) are placed on powerful inhaled corticosteroid therapy to ease symptoms. But new research suggests the treatment might raise their odds for bone... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 13, 2018 Category: General Medicine Source Type: news

Teva launches breath-activated asthma aerosol in U.S.
Teva Pharmaceuticals (NYSE:TEVA) has launched its Qvar RediHaler inhalation aerosol in the U.S., marking the first time a breath-actuated inhaled corticosteroid is available for asthma patients as a prophylactic therapy. In contrast to traditional metered-dose inhalers, Teva’s Qvar RediHaler sends medication into the user’s lungs as they inhale. This feature eliminates the need for hand-breath coordination, according to Teva. Get the full story at our sister site, Drug Delivery Business News. The post Teva launches breath-activated asthma aerosol in U.S. appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 12, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Teva Pharmaceuticals Source Type: news

Probiotics May Improve Pediatric AD Symptoms
(MedPage Today) -- Probiotics may also reduce need for topical corticosteroids (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - February 11, 2018 Category: Pediatrics Source Type: news

Study: Long-term use of inhaled corticosteroids may heighten risk of bone fractures in COPD patients
Researchers reported this month that in men and women with chronic obstructive pulmonary disease, long-term use of inhaled corticosteroids may be linked to an increased risk of bone fractures. Previous research has shown that the inhaled drugs, used to treat COPD, impact bone mineral density based on the dose of the corticosteroid, especially in post-menopausal women. Get the full story at our sister site, Drug Delivery Business News. The post Study: Long-term use of inhaled corticosteroids may heighten risk of bone fractures in COPD patients appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 6, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Research & Development Respiratory Novartis Source Type: news

Long-term usage of inhaled corticosteroids may increase risk of bone fractures in patients with COPD
(American College of Chest Physicians) A study published in the February journal CHEST ® suggests long-term inhaled corticosteroids (ICS) in patients with COPD may increase risk of bone fractures in both men and women. Previous studies have suggested that ICS negatively impacts bone mineral density in a dose-dependent fashion, particularly affecting postmenopausal women, but it has been unclear whether these effects translate to bone fractures. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 5, 2018 Category: International Medicine & Public Health Source Type: news

Do Corticosteroids Improve Diabetic Macular Edema Outcomes? Do Corticosteroids Improve Diabetic Macular Edema Outcomes?
Drs Matt Starr and Sophie Bakri on a randomized trial studying the value of adding intravitreal dexamethasone to anti-VEGF therapy.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2018 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Blood Eosinophil Counts Predict COPD Exacerbations, Response to Steroids Blood Eosinophil Counts Predict COPD Exacerbations, Response to Steroids
Higher blood eosinophil counts are associated with an increased risk of exacerbation and a better chance of responding to inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD), according to a post hoc analysis.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 29, 2018 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma COPD Drug Tiotropium Shows Promise in Preschoolers With Persistent Asthma
A new study provides preliminary evidence that tiotropium, a long-acting anticholinergic drug used for chronic obstructive pulmonary disease (COPD), is safe and effective in preschool-age children with asthma symptoms not well controlled by inhaled corticosteroids.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 26, 2018 Category: Consumer Health News Tags: Medscape Today News Source Type: news

EMA committee backs label change for GSK ’s Relvar Ellipta asthma therapy
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency committee has backed an updated label for its once-daily asthma therapy, Relvar Ellipta. If granted marketing authorization by the European Commission, the combination drug treatment will be approved for use in patients whose asthma is already controlled on an inhaled corticosteroid and a long-acting beta-2-agonist. Get the full story at our sister site, Drug Delivery Business News. The post EMA committee backs label change for GSK’s Relvar Ellipta asthma therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Diagnosing and Managing CIRCI in Critically Ill Patients II Diagnosing and Managing CIRCI in Critically Ill Patients II
This article provides updated recommendations for the management of acute illnesses that may be complicated by critical illness-related corticosteroid insufficiency.Critical Care Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 5, 2018 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news

A Guide To Managing RVO: Ophthalmology Times
(MedPage Today) -- Also, adding corticosteroid implant may not improve visual acuity (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - January 2, 2018 Category: Primary Care Source Type: news

Si-Bone touts BCBS SI joint fusion operation assessment rating upgrade
Si-Bone today touted that the Blue Cross Blue Shield Association assigned triangular implants for SI joint fusion, including the company’s iFuse implant, as a “moderate” quality evidence recommendation after an extensive review of safety and effectiveness data on the devices and procedures. The “moderate” grade is the second highest on BCBSA’s four-tier rating system, according to San Jose, Calif.-based Si-Bone, and requires sufficient clinical evidence to judge health outcomes with the devices. In the update, the BCBSA states that evidence is sufficient to show that the device, use...
Source: Mass Device - January 2, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Spinal Si-Bone Source Type: news

Diagnosing and Managing CIRCI in Critically Ill Patients Diagnosing and Managing CIRCI in Critically Ill Patients
This article provides updated recommendations for the diagnosis and management of critical illness-related corticosteroid insufficiency.Critical Care Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2017 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news

Corticosteroids for adult patients with advanced cancer who have nausea and vomiting (not related to chemotherapy, radiotherapy, or surgery)
This review found very low-quality evidence which neither supported nor refuted corticosteroid use in this setting. Further high quality studies are needed to determine if corticosteroids are efficacious in this setting. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 22, 2017 Category: Consumer Health News Source Type: news

FDA Axes Boxed Warning from Inhaled Corticosteroids Plus Long-Acting Beta Agonists
The FDA is removing the boxed warning from drugs containing both an inhaled corticosteroid and a long-acting beta agonist after studies found that... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 22, 2017 Category: Primary Care Source Type: news

Obesity Tied to Greater Asthma Impairment in Preschoolers
But responsiveness to inhaled corticosteroids is not reduced for overweight/obese preschoolers (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 21, 2017 Category: Respiratory Medicine Tags: Family Medicine, Nursing, Pediatrics, Pharmacy, Pulmonology, Allergy, Emergency Medicine, Journal, Source Type: news

AstraZeneca wins FDA nod to remove boxed warning from asthma drug label
After reviewing results from trials involving more than 41,000 asthma patients, the FDA has agreed to remove the boxed warning of serious asthma-related outcomes for AstraZeneca‘s (NYSE:AZN) Symbicort product. Patients using Symbicort, which combines an inhaled corticosteroid and a long-acting beta2-adrenergic agonist in a single inhaler, did not experience a significant increase in the risk of a serious asthma-related event, according to data from four clinical trials. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca wins FDA nod to remove boxed warning from asthma drug l...
Source: Mass Device - December 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat AstraZeneca plc Source Type: news

FDA Drops Boxed Warning on LABA/ICS Asthma/COPD Meds FDA Drops Boxed Warning on LABA/ICS Asthma/COPD Meds
FDA-required postmarket safety studies find no increased risk for serious asthma-related outcomes with products containing a long-acting beta-agonist and inhaled corticosteroid.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2017 Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news

FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)
A U.S. Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. In 2011, we required the drug companies that market LABAs to conduct these trials to evaluate the safety of LABAs when used in combination with ICS, and we reviewed the results of these recently completed trials. Based on our review, the Boxed Warning, our most prominent warning, about asthma-related death has been remove...
Source: FDA Center for Drug Evaluation and Research - What's New - December 20, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs)
[04-15-2011] To further evaluate the safety of Long-Acting Beta-Agonists (LABAs) when used in combination with inhaled corticosteroids for the treatment of asthma, the U.S. Food and Drug Administration (FDA) is requiring the manufacturers of LABAs to conduct five randomized, double-blind, controlled clinical trials comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 20, 2017 Category: Drugs & Pharmacology Source Type: news

Does red cell distribution width predict outcome in traumatic brain injury: comparison to corticosteroid randomization after significant head injury - Sadaka F, Doctors N, Pearson T, Snyders B, O'Brien J.
BACKGROUND: Traumatic brain injury (TBI) is a leading cause of death and disability. The role of red cell distribution width (RDW) as a prognostic biomarker for outcome in TBI patients is unknown. Based on the corticosteroid randomization after significant... (Source: SafetyLit)
Source: SafetyLit - December 20, 2017 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Intra-Articular Corticosteroid Injections in Knee OA Intra-Articular Corticosteroid Injections in Knee OA
Intra-articular corticosteroid injections are a non-surgical treatment option for knee OA, but certain patient factors may impact efficacy.Journal of the American Academy of Orthopaedic Surgeons (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 24, 2017 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news

After FDA nod, Flexion launches osteoarthritis injection
Flexion Therapeutics (NSDQ:FLXN) today launched its Zilretta therapy designed to help patients manage pain associated with osteoarthritis of the knee. The Burlington, Mass.-based company’s extended-release intra-articular injection combines a commonly administered, short-acting corticosteroid with a polylactic-co-glycolic acid matrix using Flexion’s microsphere technology. Get the full story at our sister site, Drug Delivery Business News. The post After FDA nod, Flexion launches osteoarthritis injection appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Orthopedics Pain Management Pharmaceuticals Wall Street Beat Flexion Therapeutics Source Type: news

Corticosteroids do not increase risk of bone fractures
According to a study, published inJAMA Pediatrics, children on daily inhalable corticosteroids do not have an increased risk of bone fractures.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - November 16, 2017 Category: Endocrinology Source Type: news

Inhaled Corticosteroids Not Linked to Fracture in Children
Systemic, but not inhaled, corticosteroids associated with higher fracture risk in pediatric asthma patients (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - November 14, 2017 Category: Respiratory Medicine Tags: Family Medicine, Nursing, Orthopedics, ENT, Pediatrics, Pharmacy, Pulmonology, Radiology, Allergy, Emergency Medicine, Journal, Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate ® (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Positive Opinion Based on Five Studies Demonstrating Nplate Reduces Rates of Bleeding in Children With Rare Blood Disorder THOUSAND OAKS, Calif., Nov. 10, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for Nplate® (romiplostim) to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura (ITP) for patients one year of age and older who are refractory to other treatments (e.g., corticosteroids, immunoglobulins). T...
Source: Amgen News Release - November 10, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Allergy Experts: Single Drug Best for Allergic Rhinitis
(MedPage Today) -- AAAAI, ACAAI advise against intranasal corticosteroid with oral antihistamine (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - November 9, 2017 Category: Allergy & Immunology Source Type: news

Topical corticosteroids reduce retinoid irritation, study shows
Transient topical corticosteroids could take edge off severe irritation from topical retinoid acne treatment without decreasing efficacy. (Source: Dermatology Times)
Source: Dermatology Times - November 1, 2017 Category: Dermatology Source Type: news

Corticosteroids for Treatment of Sore Throat Corticosteroids for Treatment of Sore Throat
Do the benefits outweigh the potential risks of using corticosteroids as an adjunct treatment for acute sore throat?The BMJ (formerly known as the British Medical Journal) (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 13, 2017 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Boehringer Ingelheim, Anthem partner for largest real-world COPD trial
As part of a research collaboration launched in 2014, Boehringer Ingelheim and Anthem have partnered to study people with chronic obstructive pulmonary disease in real-world settings to assess how commonly-prescribed drugs may reduce the occurrence of COPD exacerbations. The team, which also includes Anthem’s outcomes research subsidiary HealthCore, plans to investigate whether adding an inhaled corticosteroid to a LAMA-LABA combination provides a meaningful benefit – a question under debate in the respiratory space. Get the full story at our sister site, Drug Delivery Business News. The post Boehring...
Source: Mass Device - October 12, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Anthem Inc. Boehringer Ingelheim Pharmaceuticals Source Type: news

Corticosteroids vs. NSAIDs
Title: Corticosteroids vs. NSAIDsCategory: MedicationsCreated: 10/12/2017 12:00:00 AMLast Editorial Review: 10/12/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 12, 2017 Category: Drugs & Pharmacology Source Type: news

First UK guideline published for lupus management in adults
The smallest effective dose of corticosteroids should be used to treat adult patients with lupus, according to the first ever UK guideline specifically for the management of the condition. (Source: Nursing Times)
Source: Nursing Times - October 9, 2017 Category: Nursing Source Type: news

How Common Is Hereditary Angioedema?
Discussion Angioedema is edema that is non-pitting, self-limited occurring in non-dependent areas usually in an asymmetric distribution usually on the lips, face, hands, feet, genitals and also in the bowel. It usually develops over minutes to hours (often 1-2 hours) with resolution usually within 24-48 hours. Angioedema often occurs with urticaria but 20% of patients may have isolated angioedema. Acute allergic angioedema is often caused by drugs (including antibiotics and non-steroidal anti-inflammatory drugs), foods, infections, insects, various organic substances (i.e. latex, preservatives, formaldehyde, etc.), and oth...
Source: PediatricEducation.org - October 9, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA OKs First Extended-Release Corticosteroid Shot for Knee OA FDA OKs First Extended-Release Corticosteroid Shot for Knee OA
Triamcinolone acetonide extended-release injectable suspension (Zilretta) is a nonopioid option that provides knee OA pain relief over 12 weeks.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 6, 2017 Category: Universities & Medical Training Tags: Rheumatology News Alert Source Type: news

Vitamin D may prevent asthma worsening for some
Conclusion This review gathers the available trial evidence to address the specific question of whether giving people with asthma vitamin D supplements could have an effect on how many asthma exacerbations they have. The review has many strengths. It only included double-blind trials, where participants and assessors didn't know if people were taking vitamin D or a placebo. Researchers also made careful attempts to gather all relevant data and information on confounding factors, and all but one trial had a low risk of bias. But there are some limitations to bear in mind: With the relatively small number of trials and par...
Source: NHS News Feed - October 5, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news

LAMA Plus LABA Tied to Fewer Exacerbations in Stable COPD
Also might result in greater improvement in FEV1 than LABA plus corticosteroids (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 4, 2017 Category: Respiratory Medicine Tags: Family Medicine, Geriatrics, Internal Medicine, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Hip pain in young athletes: Q & A with a sports medicine specialist
When your child plays a sport, it’s often hard to tell where everyday aches and pains end and a potentially serious injury begins. Bumps and bruises are anything but rare in contact sports, and muscle soreness can be a common complaint for any young athlete — especially given the rigor of youth athletics these days. So how do you know when your child’s hip pain is due to an actual injury? Dr. Mininder Kocher, orthopedic surgeon and Associate Director of the Sports Medicine Division at Boston Children’s Hospital, helps answer parents’ questions about hip pain in young athletes. What are s...
Source: Thrive, Children's Hospital Boston - October 3, 2017 Category: Pediatrics Authors: Connor Ertz Tags: Ask the Expert Child and Young Adult Hip Preservation Program Division of Sports Medicine Dr. Mininder Kocher FAI femoracetabular impingement hip dysplasia hip impingement labral tear Source Type: news

Xhance ™ (fluticasone propionate) for the Treatment of Nasal Polyps
Xhance ™ (fluticasone propionate / previously known as OPN-375), a synthetic trifluorinated corticosteroid, is indicated for the treatment of nasal polyps in patients aged 18 years or older. (Source: Drug Development Technology)
Source: Drug Development Technology - September 26, 2017 Category: Pharmaceuticals Source Type: news

Meta-Analysis: Corticosteroids Improve Pain Relief in Acute Sore Throat (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM A single dose of corticosteroids offers pain relief in patients with acute sore throat, according to a meta-analysis in The BMJ.Researchers … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - September 21, 2017 Category: Primary Care Source Type: news

Following regulatory win, GSK & Innoviva tout data for once-daily triple-med inhaler
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) notched a win this week after the FDA approved its once-daily, triple combination therapy for the treatment of chronic obstructive pulmonary disease. Last week, an EU agency recommended the inhaler’s approval. Now, the companies are touting results from a late-stage trial of Trelegy Ellipta, which is composed of an inhaled corticosteroid, a long-acting muscarinic antagonist and a long-acting beta agonist. Get the full story at our sister site, Drug Delivery Business News. The post Following regulatory win, GSK & Innoviva tout data f...
Source: Mass Device - September 20, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Boston Scientific touts 3-year Alair follow-up study results
Boston Scientific (NYSE:BSX) today released 3-year follow-up cohort results from the post-FDA approved PAS2 clinical trial of its Alair system designed for bronchial thermoplasty to treat severe persistent asthma, touting reduced severe asthma attacks, hospitalizations and ER visits. Results from the trial were recently published in the European Respiratory Journal, the Marlborough, Mass.-based company said. The PAS2 trial is an open-label study which enrolled patients at 27 North American centers, with 95% of the recruited patients considered severe asthmatics. Boston Scientific said that data from the cohort co...
Source: Mass Device - September 18, 2017 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Respiratory Boston Scientific Source Type: news

GSK ’s triple-med COPD inhaler wins recommendation for approval in EU
GlaxoSmithKline (NYSE:GSK) and Innoviva (NSDQ:INVA) said today that a European Medicines Agency panel recommended marketing authorization for the Trelegy Ellipta triple-combination inhaler for adults with COPD. The device uses fluticasone furoate, umeclidinium and vilanterol to help adults with COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist. It’s also the first once-daily single inhaler triple therapy to win a positive opinion by the Committee for Medicinal Products for Human Use, the companies reported. Get the full story at our sister...
Source: Mass Device - September 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat GlaxoSmithKline plc Innoviva Source Type: news

Interventions for treating tuberculous pericarditis
(Liverpool School of Tropical Medicine) Researchers from South Africa and Canada have carried out a Cochrane review update to assess the safety and effectiveness of corticosteroids for treating tuberculous pericarditis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 14, 2017 Category: Infectious Diseases Source Type: news

Expensive drug driving up Medicare expenditures without evidence of greater efficacy
(Oregon State University) Medicare spent more than $1 billion over a five-year period on a high-priced drug that has not been proven more effective for a collection of inflammatory conditions than much less expensive corticosteroids. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 11, 2017 Category: International Medicine & Public Health Source Type: news

Oral Corticosteroids of No Benefit in Nonasthmatic Adults with Lower Respiratory Tract Infection (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH Oral corticosteroids offer no benefit to nonasthmatic adults with acute lower respiratory tract infection, according to a placebo-controlled trial in JAMA … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - August 23, 2017 Category: Primary Care Source Type: news

Oral Corticosteroids No Benefit for LRI in Non - Asthmatic Adults
No decrease in cough duration, severity for adults without asthma with lower respiratory tract symptom (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 23, 2017 Category: Respiratory Medicine Tags: Family Medicine, Infections, Internal Medicine, Emergency Medicine, Nursing, ENT, Pharmacy, Pulmonology, Journal, Source Type: news

Corticosteroid injection may offer little advantage for Morton ’s neuroma patients treated with local anesthetic
According to a study published online in the journal Foot & Ankle International, corticosteroid injection plus local anesthetic may not be superior to local anesthetic alone in terms of pain and function for patients with Morton’s neuroma.  (Source: Orthogate - Latest News)
Source: Orthogate - Latest News - August 20, 2017 Category: Orthopaedics Tags: Featured Editors Choice News Source Type: news